C4 Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ExhibitNumber | Description | Form | FileNumber | Date ofFiling | ExhibitNumber | FiledHerewith |
|---|---|---|---|---|---|---|
| 3.1 | Fifth Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39567 | 10/06/2020 | 3.1 | |
| 3.2 | Second Amended and Restated By-laws of the Registrant | S-1 | 333-248719 | 09/10/2020 | 3.5 | |
| 4.1 | Amended and Restated Investors’ Rights Agreement among the Registrant, its warrant holder and certain of its stockholders | S-1 | 333-248719 | 09/10/2020 | 4.1 | |
| 4.2 | Stock Purchase Agreement, dated May 29, 2023, by and among C4 Therapeutics, Inc., Betta Pharmaceuticals Co., Ltd. and Betta Investment (Hong Kong) Limited. | 8-K | 001-39567 | 05/30/2023 | 10.2 | |
| 10.1† | Research Collaboration and License Agreement dated March 1, 2024, by and among C4 Therapeutics, Inc., and Merck KGaA, Darmstadt, Germany | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | |||||
| 101.CAL | Inline XBRL Taxonomy Calculation Linkbase Document | |||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||
| 101.LAB | Inline XBRL Taxonomy Label Linkbase Document | |||||
| 101.PRE | Inline XBRL Taxonomy Presentation Linkbase Document | |||||
| ExhibitNumber | Description | Form | FileNumber | Date ofFiling | ExhibitNumber | FiledHerewith |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||
† Portions of this exhibit will be omitted in accordance with the rules of the Securities and Exchange Commission.
*Exhibits 32.1 and 32.2 are being furnished herewith and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibit be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act, or the Exchange Act, except as otherwise stated in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.